Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
 Shi, J.F., K. Chen Jf Fau - Canfell, X.-X. Canfell K Fau - Feng, J.-F. Feng Xx Fau - Ma, Y.-Z. Ma Jf Fau - Zhang, F.-H. Zhang Yz Fau - Zhao, R. Zhao Fh Fau - Li, L. Li R Fau - Ma, Z.-F. Ma L Fau - Li, J.-B. Li Zf Fau - Lew, Y. Lew Jb Fau - Ning, Y.-L. Ning Y Fau - Qiao, and Y.L. Qiao, Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study[J]. (1472-6963 (Electronic)).
 Small, W.J.A.-O., et al., Cervical cancer: A global health crisis. (1097-0142 (Electronic)).
 Henrique, R., S.P. Nunes, and C. Jerónimo, MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges[J]. Eur Urol, 2019. 75(2): p. 251-252.
 Li, Y., S. Zhang, Y. Wang, J. Peng, F. Fang, and X. Yang, MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway[J]. BMC Cancer, 2018. 18(1): p. 1294.
 Stordal, B. and M. Davey, Understanding cisplatin resistance using cellular models[J]. IUBMB Life, 2007. 59(11): p. 696-9.
 Bompiani, K.M., C.Y. Tsai, F.P. Achatz, J.K. Liebig, and S.B. Howell, Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity[J]. Metallomics, 2016. 8(9): p. 951-62.
 Lee, Y.Y., C.H. Choi, I.G. Do, S.Y. Song, W. Lee, H.S. Park, T.J. Song, M.K. Kim, T.J. Kim, J.W. Lee, D.S. Bae, and B.G. Kim, Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy[J]. Gynecol Oncol, 2011. 122(2): p. 361-5.
 Zhu, H., H. Luo, W. Zhang, Z. Shen, X. Hu, and X. Zhu, Molecular mechanisms of cisplatin resistance in cervical cancer[J]. Drug Des Devel Ther, 2016. 7(10): p. 1885-95.
 Ulitsky, I. and D.P. Bartel, lincRNAs: genomics, evolution, and mechanisms. (1097-4172 (Electronic)).
 Agostini, M., C.A.-O. Ganini, E. Candi, and G. Melino, The role of noncoding RNAs in epithelial cancer[J]. (2058-7716 (Print)).
 Beermann, J., et al., Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. (1522-1210 (Electronic)).
 Lai, E.C., Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation[J]. (1061-4036 (Print)).
 Ulitsky, I. and D.P. Bartel, lincRNAs: genomics, evolution, and mechanisms[J]. (1097-4172 (Electronic)).
 Chen, B. and S. Huang, Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer[J]. (1872-7980 (Electronic)).
 Hansen, T.B., et al., Natural RNA circles function as efficient microRNA sponges. (1476-4687 (Electronic)).
 Hansen, T.B., B.H. Jensen Ti Fau - Clausen, J.B. Clausen Bh Fau - Bramsen, B. Bramsen Jb Fau - Finsen, C.K. Finsen B Fau - Damgaard, J. Damgaard Ck Fau - Kjems, and J. Kjems, Natural RNA circles function as efficient microRNA sponges[J]. (1476-4687 (Electronic)).
 Du, H. and Y. Chen, Competing endogenous RNA networks in cervical cancer: function, mechanism and perspective[J]. (1029-2330 (Electronic)).
 Yang, F., et al., MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes. (1643-3750 (Electronic)).
 Yang, F., L. Guo, Y. Cao, S. Li, J. Li, and M. Liu, MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes[J]. (1643-3750 (Electronic)).
 Chi, C., M. Mao, Z. Shen, Y. Chen, J. Chen, and W. Hou, HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells[J]. Hum Gene Ther, 2018.
 Ma, Z.A.-O.X., G. Gu, W. Pan, and X. Chen, LncRNA PCAT6 Accelerates the Progression and Chemoresistance of Cervical Cancer Through Up-Regulating ZEB1 by Sponging miR-543[J]. (1178-6930 (Print)).
 Feng, Y., et al., Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin. Arch Biochem Biophys, 2017. 623-624: p. 20-30.
 Ashburner, M., et al., Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. (1061-4036 (Print)).
 The Gene Ontology Resource: 20 years and still GOing strong. (1362-4962 (Electronic)).
 Kanehisa, M., Y. Sato, M. Furumichi, K. Morishima, and M. Tanabe, New approach for understanding genome variations in KEGG[J]. (1362-4962 (Electronic)).
 Zhu, H., H. Luo, W. Zhang, Z. Shen, X. Hu, and X. Zhu, Molecular mechanisms of cisplatin resistance in cervical cancer[J]. (1177-8881 (Electronic)).
 Hua, X., Y. Sun, J. Chen, Y. Wu, J. Sha, S. Han, and X. Zhu, Circular RNAs in drug resistant tumors[J]. (1950-6007 (Electronic)).
 Huang, X., et al., Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. (1476-4598 (Electronic)).
 Kun-Peng, Z., M. Xiao-Long, and Z. Chun-Lin, Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1[J]. (1449-2288 (Electronic)).
 Su, Y., et al., Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance. (1449-2288 (Electronic)).
 Shao, F., M. Huang, F. Meng, and Q. Huang, Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma[J]. (1663-9812 (Print)).
. Liu, F., et al., Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. (1945-4589 (Electronic)).
. Xiaoran Long, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res . 2019, 38(1):345.
. Xiaoqiong Luo, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int . 2019 Dec 3;19:323.
. Kristensen, L.A.-O., et al., The biogenesis, biology and characterization of circular RNAs. (1471-0064 (Electronic)).
. Qu, S., et al., The emerging landscape of circular RNA in life processes. (1555-8584 (Electronic)).
. Qi, X., et al., ceRNA in cancer: possible functions and clinical implications. (1468-6244 (Electronic)).
. Chen, L., et al., circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. (1476-5594 (Electronic)).
. Cheng, Z., et al., circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. (2041-1723 (Electronic)).
. Zheng, Q., et al., Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. (2041-1723 (Electronic)).
. Yu, M., et al., MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin. (1179-1322 (Print)).